SCHEMBL1582250

SCHEMBL1582250

O=S(=O)(CCCOCc1ccccc1)c1ccc(/C(=C\C2CCCC2)CO)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ TEAD3 Q99594 2/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ FKBP1A P62942 2/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ GBA1 P04062 2/20 0.33
▸ UGCG Q16739 2/20 0.33
▸ GBA2 Q9HCG7 2/20 0.33
▸ MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582252 1.00 TSHR (0.36) TSHRHSD17B10LMNAHDAC1HDAC8
SCHEMBL1581867 0.81 LMNA (0.41) TSHRHSD17B10LMNAHDAC1HDAC8
SCHEMBL4486333 0.72 KMT2A (0.47) KMT2A
SCHEMBL1582005 0.72 KMT2A (0.47) KMT2A
SCHEMBL1581684 0.71 HTR7 (0.37) LMNAPOLBRAB9AHTR7ALDH1A1
SCHEMBL14744152 0.71 LMNA (0.46) TSHRHSD17B10LMNAHDAC1HDAC8
SCHEMBL4483872 0.71 KMT2A (0.49) KMT2AMEN1
SCHEMBL1581752 0.71 KMT2A (0.49) KMT2AMEN1
SCHEMBL1581754 0.71 KMT2A (0.49) KMT2AMEN1
SCHEMBL2662191 0.69 HTR7 (0.37) LMNAPOLBRAB9AHTR7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 — — EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 — — US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 — — US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 — — EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 TSHR 2867/4885HSD17B10 1149/4885LMNA 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback